Aminocaproic acid - instructions for use, dose, side effects, contraindications

Has a hemostatic effect. It inhibits the conversion of fibrinolysin to fibrinolysin, apparently due to the inhibition of the activator of this process, and also has a direct inhibitory effect on fibrinolysin; inhibits the activating action of streptokinase, urokinase and tissue kinases on fibrinolysis, neutralizes the effects of kallikrein, trypsin and hyaluronidase, reduces the permeability of capillaries. Has anti-allergic activity, improves the antitoxic function of the liver. With intravenous administration, the effect is manifested after 15-20 minutes.

Pharmacokinetics:

The drug is quickly excreted by the kidneys - 40 - 60% of the administered amount is released in 4 hours unchanged. If the excretory function of the kidneys is disturbed, the concentration of aminocaproic acid in the blood increases significantly.

Indications:

Bleeding (hyperfibrinolysis, hypo- and afibrinogenemia).Bleeding during surgical interventions on organs rich in fibrinolysis activators (heart, brain and spinal cord, lungs, thyroid and pancreas, prostate gland), vessels in the ear, throat, nose; Diseases of internal organs with hemorrhagic syndrome. Premature detachment of the placenta, prolonged retention in the uterine cavity of the dead fetus, complicated abortion. To prevent secondary hypofibrinogenemia in massive transfusions of canned blood.

Contraindications:

Hypersensitivity to the drug, hypercoagulation (thrombosis, thromboembolism), propensity to thrombosis and thromboembolic diseases, cerebral circulation disorders, renal dysfunction, kidney disease with impaired excretory function, disseminated intravascular coagulation.

Carefully:

Arterial hypotension, valvular heart disease, hematuria, bleeding from the upper urinary tract unidentified etiology, liver failure, chronic renal failure.

Pregnancy and lactation:

The drug penetrates the placental barrier and into breast milk, so the drug is contraindicated in pregnancy and during breastfeeding.

Dosing and Administration:

Introduced intravenously, drip.

For acute bleeding, 4-5 g (diluted in 80-100 ml of 0.9% sodium chloride solution) of the drug for 1 hour, then if necessary - 1 g (20 ml) of the drug every hour for 8 hours or until complete stoppage bleeding. With continued bleeding, infusions are repeated every 4 hours.

The daily intake for adults is 5-30 g.

Children at the rate of 100 mg / kg body weight in the first hour, then 33 mg / kg / h, the maximum daily dose of -18 g / m² surface of the body.

Duration of treatment is 3-14 days.

Side effects:

Dizziness, tinnitus, headache, nausea, diarrhea, nasal congestion, skin rash, lowering of blood pressure, orthostatic hypotension, convulsions, rhabdomyolysis, myoglobinuria, acute renal failure, subendocardial hemorrhage.

Overdose:

If the initiation of aminocaproic acid develops the initial signs of toxic effects, discontinue the drug and conduct symptomatic treatment.

Interaction:

Anticoagulants of direct and indirect action, antiaggregants decrease efficiency.

The administration of the drug can be combined with the administration of glucose solution, hydrolysers and anti-shock solutions. In acute fibrinolysis, when the fibrinogen content in the blood drops sharply, administration of aminocaproic acid must be supplemented by the subsequent infusion of fibrinogen in an average daily dose of 2-4 g (maximum dose of 8 g).

Special instructions:

It is not advisable to use aminocaproic acid in women to prevent increased blood loss during childbirth, since there may be thromboembolic complications in the postpartum period.

With prolonged therapy, it is necessary to monitor the blood picture.

It is not recommended to administer aminocaproic acid in hematuria due to the danger of developing acute renal failure.

The purpose of the drug requires checking the fibrinolytic activity of blood and the concentration of fibrinogen in the blood. With intravenous administration, coagulogram monitoring is necessary, especially in coronary heart disease, after myocardial infarction, in pathological processes in the liver.

Effect on the ability to drive transp. cf. and fur:

Given that the drug can cause dizziness, headache,lowering blood pressure is not recommended when taking aminocaproic acid to drive vehicles and engage in potentially dangerous activities that require increased concentration and speed of psychomotor reactions.

Form release / dosage:

Solution for infusions 50 mg / ml.

Packaging:

100 ml, 200 ml in glass bottles for blood, transfusion and infusion preparations, corked with rubber stoppers and crimped with aluminum caps. A bottle with instructions for use is placed in a pack of cardboard.

For hospitals: 35 bottles of 100 ml or 28 bottles of 200 ml, together with an equal number of instructions for use, are placed in boxes of corrugated cardboard with gaskets, with baffles or with grids ("nests") without pre-packing.

Storage conditions:

In the dark place at a temperature of 0 to 20 ° C in an upright position with a stopper up.

Keep out of the reach of children.

Shelf life:

3 years. After the expiry date, the drug should not be used.

Terms of leave from pharmacies:On prescription

Registration number:P N003799 / 01

Date of registration:02.10.2009 / 24.04.2012

Expiration Date:Unlimited

The owner of the registration certificate:DALHIMFARM, OJSC DALHIMFARM, OJSC Russia

Manufacturer: & nbsp

DALHIMFARM, OJSC Russia

Information update date: & nbsp07.08.2017

Illustrated instructions

Instructions

Aminocaproic acid (Aminocaproic acid)